ARIA News Alert Ariad Pharmaceuticals (ARIA) 6.81 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ariad Pharmaceuticals (ARIA) 6.81 $ARIA

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 8:18AM CST

CYTK: 5.87 (+0.35), JRJC: 5.81 (-0.11), RDN: 16.78 (+0.18), CHK: 19.84 (-0.45), VNDA: 14.69 (+1.11), DRL: 3.38 (-0.02), ARIA: 6.81 (+0.15), ICLD: 3.00 (-0.02), NQ: 4.32 (-0.36)

Ariad Pharma inks commercialization deal in Asia
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 6:43AM CST

ARIA: 6.81 (+0.15)

ARIAD and Otsuka Announce Co-Development and Commercialization Agreement for Iclusig to Treat Leukemias in Japan and Nine Other Asian Countries
Business Wire - Tue Dec 23, 6:00AM CST
--Otsuka to obtain rights in ten Asian countries to Iclusig, a newest-generation treatment for patients with refractory chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia
ARIA: 6.81 (+0.15)

ARIAD To Present at The 33rd Annual J.P. Morgan Healthcare Conference
Business Wire - Mon Dec 22, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the 33rd Annual J.P. Morgan Healthcare Conference being held in San Francisco. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company's business on Wednesday, January 14 at 3:00 p.m. (PT).
JPM: 62.48 (unch), ARIA: 6.81 (+0.15)

Adam Feuerstein's 2014 Biotech Stock Report Card (No Grading on a Curve)
at The Street - Fri Dec 19, 8:02AM CST
Good calls: Vertex, InterMune, Chelsea, Galena, Exact Sciences. The bad calls: Avanir, Amarin, Exelixis and the bursting biotech stock bubble.
VRTX: 115.15 (+1.40), GALE: 1.49 (-0.02), EXAS: 27.60 (+0.39), ARIA: 6.81 (+0.15), MNKD: 5.68 (+0.18)

Biotech Stocks Technical Insight -- ARIAD Pharma, Geron, PDL BioPharma, Cytori Therapeutics, and Navidea Biopharma
PR Newswire - Thu Dec 18, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Geron Corporation (NASDAQ: GERN), PDL BioPharma Inc. (NASDAQ: PDLI), Cytori Therapeutics Inc. (NASDAQ: CYTX), and Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Wednesday, December 17, 2014, surged as the Dow Jones Industrial Average finished at 17,356.87, up 1.69% and the NASDAQ Composite closed at 4,644.31, up 2.12%. The S&P 500 finished the session 2.04% higher at 2,012.89. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Index ended the day at 791.66, up 1.90%, with the index advancing 6.28% in the previous three months. Register for your complimentary reports on these five stocks at:
NAVB: 2.00 (+0.02), CYTX: 0.48 (-0.01), GERN: 3.06 (+0.05), ARIA: 6.81 (+0.15), PDLI: 7.61 (unch)

Does George Soros Think Biotech's Bull Run Is Finally Coming to an End?
George Budwell, The Motley Fool - Motley Fool - Mon Dec 15, 6:45AM CST
To say that biotech stocks have performed well as a group over the last two years is an understatement; they have absolutely crushed the broader markets. For example, the iShares Nasdaq Biotech Index has more than tripled the performance of the ...
SRPT: 13.88 (+0.47), IBB: 299.80 (+5.12), ARIA: 6.81 (+0.15), CELG: 109.60 (+3.48)

SmarTrend Watching for Potential Rebound in Shares of Ariad Pharmaceuticals After 7.76% Loss
Comtex SmarTrend(R) - Thu Dec 11, 4:40PM CST
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $6.34 to a high of $6.88. Yesterday, the shares fell 7.8%, which took the trading range below the 3-day low of $6.80 on volume of 13.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ARIA: 6.81 (+0.15)

Energy Stocks Pare Gains as Crude Oil Closes Below $60 For First Time in Five Years
at The Street - Thu Dec 11, 1:52PM CST
Energy stocks are leading the markets higher, a day after they sparked a selloff.
SPLS: 17.82 (-0.01), DAL: 48.05 (+0.92), XOM: 93.78 (-0.81), COP: 70.13 (-0.92), LLY: 70.16 (+0.42), LULU: 54.40 (-0.16), LUV: 41.66 (+0.68), URBN: 34.15 (-0.53), EBAY: 57.10 (-0.12), AAL: 51.43 (+1.22), ODP: 8.75 (+0.06), ARIA: 6.81 (+0.15), CVX: 113.47 (-0.48), WAG: 76.67 (+0.16), XLE: 80.13 (-0.59)

Nasdaq stocks posting largest percentage decreases
AP - Thu Dec 11, 12:19PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
AMBA: 52.05 (+0.72), LNCO: 10.87 (-0.44), MCEP: 6.07 (-0.12), LAKE: 8.94 (+0.07), CLDN: 18.54 (+0.85), BRID: 7.01 (-0.45), ARIA: 6.81 (+0.15), LINE: 10.93 (-0.32), MIND: 5.77 (+0.14), DGLY: 15.62 (+0.82), ALLT: 9.28 (+0.15), ROSE: 23.18 (-0.45)

Ariad slumps after analyst downgrade
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 9:25AM CST

IBB: 299.80 (+5.12), ARIA: 6.81 (+0.15)

Will Ariad Pharmaceuticals (ARIA) Stock be Affected Today by This Analyst Action?
at The Street - Thu Dec 11, 8:14AM CST
Shares of Ariad Pharmaceuticals (ARIA) are down after Credit Suisse downgraded the global oncology company to 'underperform' from 'neutral' and lowered its price target to $6 from $8.
ARIA: 6.81 (+0.15)

Downgrade Alert for Ariad Pharmaceuticals (ARIA)
Comtex SmarTrend(R) - Thu Dec 11, 6:54AM CST
Ariad Pharmaceuticals (NASDAQ:ARIA) was downgraded from Neutral to Underperform at Credit Suisse today. The stock closed yesterday at $7.02 on volume of 4.6 million shares, below average daily volume of 6.3 million. In the past 52 weeks, Ariad Pharmaceuticals share prices have been bracketed by a low of $3.80 and a high of $9.83 and closed yesterday at $7.02, 85% above that low price. Over the last five market days, the 200-day moving average (MA) has gone down 0.3% while the 50-day MA has advanced 1.5%.
ARIA: 6.81 (+0.15)

Uptrend Call Working As Ariad Pharmaceuticals Stock Rises 22.6% (ARIA)
Comtex SmarTrend(R) - Tue Dec 09, 5:08PM CST
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on October 29th, 2014 at $5.92. In approximately 1 month, Ariad Pharmaceuticals has returned 22.57% as of today's recent price of $7.25.
ARIA: 6.81 (+0.15)

Long-term follow up data for Iclusig positive
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 9:54AM CST

ARIA: 6.81 (+0.15)

ARIAD Announces Follow-up Data from Phase 1 and PACE Trials of Ponatinib in Patients with T315I Mutation in Chronic Myeloid Leukemia
Business Wire - Tue Dec 09, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced safety and efficacy follow-up data on Iclusig(R) (ponatinib), its approved BCR-ABL inhibitor, in patients with a baseline T315I mutation from its Phase 1 and Phase 2 PACE trials in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
ARIA: 6.81 (+0.15)

ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid Leukemia from Phase 1 Clinical Trial
Business Wire - Tue Dec 09, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced long-term follow up data from the Phase 1 trial of Iclusig(R) (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that with a median follow-up of four years in chronic phase CML (CP-CML) patients, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options and that responses have been maintained in CP-CML patients (n=43) with 72 percent having a major cytogenetic response (MCyR), 65 percent having a complete cytogenetic response (CCyR) and 56 percent having a major molecular response (MMR). Long-term safety data show that careful benefit-risk evaluations should guide decisions to use and maintain ponatinib therapy, particularly in patients who may be at increased risk for arterial thrombotic events.
ARIA: 6.81 (+0.15)

ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial
Business Wire - Mon Dec 08, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced long-term follow up from its pivotal Phase 2 trial of Iclusig(R) (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that with a median follow-up of approximately 3 years for chronic-phase CML (CP-CML) patients in the trial, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options. Deep and durable responses have been maintained in CP-CML patients with 83 percent of CP-CML patients who achieved a response, estimated to remain in major cytogenetic response (MCyR) at three years.
ARIA: 6.81 (+0.15)

Why Ariad Pharmaceuticals, Inc. Stock Catapulted 19% Higher in November
Sean Williams, The Motley Fool - Motley Fool - Fri Dec 05, 7:36AM CST
ARIA data by YCharts What: Shares of Ariad Pharmaceuticals , a biopharmaceutical company focused on developing therapies to treat cancer, surged by 19% in November according to data from S&P Capital IQ after reporting market-topping...
ARIA: 6.81 (+0.15)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 161

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 78

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 139

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 161

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 121

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 157

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 92

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 154

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Market Sentiment Around Primerica's Stock

Updated Category News Views 89

Market Sentiment and Primerica's Stock Insights Primerica (NYSE: PRI) has seen a notable change in its short interest recently. The short percent of float has decreased by 11.7% since the last reporting period, indicating a shift in trader sentiment. Currently, there are approximately 219 thousand shares sold short, which accounts for about 0.83% of all regular shares...

Continue Reading
Applied Digital Corporation Secures Major $5 Billion Contract

Updated Category News Views 189

Applied Digital Corporation Celebrates New Milestone Applied Digital Corporation (NASDAQ: APLD) has secured a transformative contract that shines a spotlight on its ambitious Polaris Forge 2 Campus project. The deal, valued at a staggering $5 billion, involves a 15-year lease agreement with a U.S.-based investment-grade hyperscaler. This significant venture is poised to...

Continue Reading
Carnival Cruise Lines on Track for Major Gains in 2025

Updated Category News Views 611

Carnival Cruise Lines Poised for Growth in 2025 Carnival Cruise Lines (NYSE: CCL) has seen a remarkable increase in its share price, rising by approximately 50% as we head into 2024. This upward trend reflects a resilient business model and robust operational efficiencies. Expectations for fiscal 2025 are bolstered by the ongoing normalization of the cruise industry...

Continue Reading
CAS Space Chairman Aims to Build Rockets Like Cars

Updated Category News Views 24

Rocket Science on the Fast Lane Welcome to a new chapter in the space race, where Yang Yiqiang of CAS Space is steering the vision. When you think of rockets, you might imagine a symphony of math and metal, far removed from the everyday grind of car production. But Yang, itching to shuffle that status quo, wants rockets rolling off assembly lines like cars—an idea...

Continue Reading
Vodafone's Strategic Cash Tender Offers Announced for 2025-2028 Bonds

Updated Category News Views 507

Vodafone Group Initiates Cash Tender Offers for Outstanding Notes Vodafone Group Plc, a prominent telecommunications company, has announced its plans to launch cash tender offers for its outstanding U.S. dollar notes due in 2025 and 2028. This strategic move is aimed at managing its debt efficiently, particularly focusing on reducing near-term maturities that could impact...

Continue Reading